Surrogate Endpoints Mark Rothmann* Minimal Residue Disease Workshop April 18, 2012 *The views expressed in this presentation are those of the presenters and do not necessarily represent those of the U.S. Food and Drug

First Page		Document Content
Epidemiology Clinical trials Medical statistics Medical research Medical terms Surrogate endpoint Clinical endpoint Biomarker Imaging biomarker Medicine Biology Health		Surrogate Endpoints Mark Rothmann* Minimal Residue Disease Workshop April 18, 2012 *The views expressed in this presentation are those of the presenters and do not necessarily represent those of the U.S. Food and Drug Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 48,49 KB Share Document on Facebook

	THE BEST RESOURCE: HARMONIZING BIOMARKER TERMINOLOGY DocID: 1vrpl - View Document
	MEDIA INFORMATION Published: 00:01 hrs CEST Sunday, 22 April 2018 Gene linked to fatal outcomes in patients with P. aeruginosa bloodstream infection may be used as prognostic biomarker and treatment target Madrid, Spain: DocID: 1vqLR - View Document
	TUESDAY POSTER PRESENTATION TP01 - Cancer, Clinical and Translational Proteomics MO01-001 Verification of colorectal cancer biomarker candidates in plasma/serum extracellular vesicles by targeted proteomics Takeshi Tomon DocID: 1v6qe - View Document
	Stressed about Picking an Oxidative Damage Assay? A Guide to Finding the Right Biomarker to Detect in Your Application Oxidative stress can be evaluated directly by measuring reactive oxygen species (ROS) or indirectly b DocID: 1v559 - View Document
	Media Planet – Der Krebsratgeber http://www.krebsratgeber.at/praezisionsmedizin-smarte-biomarker-nanotechnologien-und-mehr DocID: 1v1Po - View Document